WARNING: HEPATOTOXICITY– Severe and sometimes fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function prior to and during treatment. Interrupt and then reduce or discontinue STIVARGA® for hepatotoxicity as manifested by elevated liver function tests or hepatocellular necrosis, depending upon severity and persistence. Continue reading below.


When is it time to act?

Metastatic colorectal cancer (mCRC)

For the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.

Gastrointestinal stromal tumor (GIST)

For the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.



Available for eligible patients. Learn more about patient eligibility.
Enrollment Form (PDF) REACH® Enrollment Form (PDF)
Can be used to register the patient with REACH, which facilitates shipment of STIVARGA once insurance coverage is confirmed or the patient qualifies for the REACH Co-pay Assistance Program.
REACH form for dispensing pharmacies (PDF) REACH Form for Dispensing Pharmacies (PDF)
Communicates necessary patient and physician information to STIVARGA-dispensing pharmacies.